Hidradenitis Suppurativa and Zinc: A New Therapeutic Approach
A Pilot StudyBrocard A. · Knol A.-C. · Khammari A. · Dréno B.
aDepartment of Dermatology and bLaboratory of Dermato-Immunology, INSERM U601, CHU Hôtel-Dieu, Nantes, France
Background: Hidradenitis suppurativa (Verneuil’s disease) is a chronic suppurative dermatosis involving apocrine glands with a severe impact on the quality of life, which is enhanced by the fact that the drugs usually prescribed are poorly effective. Objective: We discuss a new therapeutic approach based on zinc salts. Methods: We performed a pilot study on 22 patients, mainly from grade I or II in Hurley’s classification. All included patients had previously been prescribed a treatment (antibiotic, isotretinoin, surgery or anti-androgens), which was inefficient. They were then treated with 90 mg of zinc gluconate per day (15 mg zinc per Rubozinc® capsule). Results: We observed a clinical response in all patients, with 8 complete remissions (CR) and 14 partial remissions (PR). When CR was obtained, the treatment was progressively decreased (average of 3.5 capsules/day); 4/22 patients experienced side-effects, mainly gastro-intestinal. Conclusion: Zinc salts could provide a new therapeutic alternative for the treatment of hidradenitis suppurativa.
Department of Dermatology, Place Alexis-Ricordeau
FR–44093 Nantes (France)
Tel. +33 2 40 08 31 16, Fax +33 2 40 08 31 17
E-Mail firstname.lastname@example.org, email@example.com
Received: February 24, 2006
Accepted: December 29, 2006
Number of Print Pages : 3
Number of Figures : 0, Number of Tables : 0, Number of References : 11
Vol. 214, No. 4, Year 2007 (Cover Date: April 2007)
Journal Editor: Saurat, J.-H. (Geneva)
ISSN: 1018–8665 (print), 1421–9832 (Online)
For additional information: http://www.karger.com/DRM